San Diego-dependent Viking Therapeutics marked alone as a serious competitor during the weight loss drug sector in February following revealing promising data from the mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection As well as in March the company un